Lifeline Biotechnologies Inc (LLBO)

[pennytradex]

LLBO - Lifeline Biotechnologies Chart And DD Analysis

Business Description: Development of system, The First Warning System(TM) for assisting in the early detection of breast cancer.

Ever had a Mammogram. Painful to say the least. And the results from the test are iffy at best. Currently, it is widely recognized that mammograms miss an estimated 20 to 30% of the breast cancers. That means 20 to 30 out of 100 women who take the test don’t really know if they have the cancer or not, even after taking the test. That is a terrible score card, especially when early detection in breast cancer is one of the keys for a successful cure. Lifeline Biotechnologies has developed a technology that, as is described in the PR release below: “The software has achieved the robust capability of identifying and classifying tissue abnormalities of the breast with sensitivities (ability to identify) of 95% to 100% and specificities (verify) of 87% to 90%. Currently, it is widely recognized that mammograms miss an estimated 20 to 30% of the breast cancers.”

Once this technology gains FDA approval I see this stock moving up quickly in PPS. I am long million shares and expect a handsome reward for holding.

PR Release August 3rd, 2009, in part - Jim Holmes, Lifeline’s CEO said that “through its consulting firm, Lifeline has submitted the First Warning System™ process and technology to the FDA. The purpose of this filing is to obtain the FDA’s opinion requesting a classification of this device. The opinion as to the classification is expected to determine the subsequent filing and registration required to clear the First Warning System™ for marketing in the United States. The FDA’s response is expected to take several months.”

Holmes went on to say, “This is a very exciting time for us and those that are interested in this innovative, leading edge, and disruptive technology. The First Warning System is a device and process which assists in the early detection of breast cancer, designed, developed and tested with approximately 700 women. This process has the potential of changing the way breast cancer is identified. After many years and many resources applied, we’ve moved to the important point of entering the process of clearance of this device with the FDA. The next step is expected to be obtaining clearance for market entry.”

Lifeline Biotechnologies previously received two patents on its First Warning System™ hardware and has in the past year filed for a patent on the technological advancements of the First Warning System ™ software. The software has achieved the robust capability of identifying and classifying tissue abnormalities of the breast with sensitivities (ability to identify) of 95% to 100% and specificities (verify) of 87% to 90%. Currently, it is widely recognized that mammograms miss an estimated 20 to 30% of the breast cancers.

Link to full news report - http://finance.yahoo.com/news/Lifeline-Biotechnologies-bw-721936416.html?x=0&.v=1

Link to Yahoo Quote and News - http://finance.yahoo.com/q?s=LLBO.PK


Chart Technical Analysis
In the 120 minute chart below the PPS is now at the support level of around .025 going back to the month of September . The PPS is starting to bounce off the support which is a good sign. I just purchased another 200,000 shares yesterday when I saw the stock was resting on it’s support. As can be seen in the chart back around the middle of September the stock quickly shot up to .008 on anticipation of the FDA response. The stock has drifted lower since then since no news has come out on the status of the FDA response, until Monday of this week, 10/26/09. The company said to be patient, the FDA is 30 to 60 days behind. Here is a quote from Jim Holmes taken out of the news release “We have checked with our FDA consulting firm, the firm that assisted us with the preparation and submission of our July 2009 filing, who advised us that the FDA is running anywhere from 30 to 60 days past the normal time expected to provide a response. We have been advised to exercise patience and we ask that our shareholders do the same. It’s been a long road and we feel we’re getting close. If the FDA is satisfied with our testing process and the supporting information is sufficient, we could proceed and file a 510(k) application immediately. However, the possibility must be considered that the FDA could request additional testing or other technical validations.”

Link to Last News Release - http://finance.yahoo.com/news/Lifeline-Biotechnologies-bw-3796082455.html?x=0&.v=1





As can be seen in the LLBO daily chart below the stock is now resting at it’s support of around .0025. The lowest support shown on the chart would be around .001, which would be the low of the bars on the left of the chart around the middle of July. There are two high bars on the chart, the 2.5 cent and the .008. If the stock gets back up to the .008 this would be around a 300% gain from this level of .0025, if it makes it back to the 2.5 cent level this would be a 1,000% gain. I like the odds here. 50% to 60% drop compared to a 300% to 1,000% gain. (if it drops to .001 I will purchase another million shares anyway).

I suspect that once this stock gains FDA approval the PPS is going to be much higher than the 2.5 cents on the chart. My own opinion of course but think of the possibilities for this company once this ground breaking technology gains FDA approval. I would suspect women will be demanding this testing process over the mammogram. Number of hospitals, clinics, cancer centers, etc, times number of units. There is a very good possibility that this stocks revenue is going to sky rocket. Read the news reports and do your own due diligence. I think that once the market starts to recognize this companies potential great things are going to happen.